<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00955773</url>
  </required_header>
  <id_info>
    <org_study_id>112110</org_study_id>
    <nct_id>NCT00955773</nct_id>
  </id_info>
  <brief_title>A Study of the GSK MEK Inhibitor GSK1120212 and Everolimus in Cancer Subjects</brief_title>
  <acronym>Cancer</acronym>
  <official_title>An Open-Label, Dose-Escalation, Phase IB II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the MEK Inhibitor GSK1120212 in Combination With Oral Everolimus in Subjects With Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the recommended dose and regimen for the orally&#xD;
      administered MEK inhibitor GSK1120212 dosed in combination with everolimus in subjects with&#xD;
      solid tumors. The escalation part of the study will determine the MTD. The combination will&#xD;
      be further explored in the expansion part in subjects with metastatic pancreatic cancer. In&#xD;
      addition, subjects with KRAS mutant non-small cell lung cancer will be enrolled.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      MEK112110 is a dose-escalation, open-label study to determine the recommended dose and&#xD;
      regimen for the orally administered MEK inhibitor GSK1120212 dosed in combination with&#xD;
      everolimus in subjects with solid tumors. This will be accomplished using a dose-escalation&#xD;
      procedure starting at low doses of GSK1120212 and everolimus. Dose escalation will continue&#xD;
      based on predefined parameters until the maximum tolerated dose is identified. The&#xD;
      recommended doses and regimens will be selected based on the safety and pharmacokinetic&#xD;
      profiles. The clinical activity of GSK1120212 dosed in combination with everolimus will be&#xD;
      explored further in an expansion cohort consisting of 20 subjects with metastatic pancreatic&#xD;
      cancer. In addition a substudy will be conducted in 40 subjects with KRAS-mutant non-small&#xD;
      cell lung cancer.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 17, 2009</start_date>
  <completion_date type="Actual">November 8, 2011</completion_date>
  <primary_completion_date type="Actual">November 8, 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AEs and changes in laboratory values and vital signs</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Response rate, CR + PR of GSK1120212 and everolimus in KRAS-mutant NSCLC.</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>GSK1120212 and everolimus PK parameters following repeat-dose (Day 15) administration of GSK1120212 and everolimus, including AUC(0-tau), Ct, Cmax, tmax, and t1/2, data permitting</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor response as defined by RECIST 1.1.</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CA 19-9 levels compared to radiological response, per RECIST 1.1, over time for each pancreatic cancer subject</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Population PK parameters, oral clearance and oral volume of distribution of GSK1120212 and everolimus will be determined. Dependant upon the final compartmental model describing GSK1120212 + everolimus, add. PK may also be estimated.</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical benefit response rate CR+PR+SD greater than 4mos</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>Group I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 to 30 solid tumor subjects will be dosed with GSK1120212 in combination with everolimus to identify Maximum Tolerated Dose. Subjects will continue on study drug until disease progression or withdraw consent.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 subjects with pancreatic cancer will receive the recommended dose identified in group I. Subjects will remain on study drug until disease progression or withdrawal from consent.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group III</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Approximately 40 lung cancer subjects will receive the recommended dose identified in group I. Subjects will remain on study until disease progression or withdrawal of consent.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK1120212 plus everolimus</intervention_name>
    <description>Dose escalation will begin at low doses of GSK1120212 and everolimus, then gradually increase in future cohorts. Dose escalation will continue until a recommended combination dose is identified. The recommended combination dose will be used to treat pancreatic and lung cancer patients in later groups in this study.</description>
    <arm_group_label>Group I</arm_group_label>
    <arm_group_label>Group II</arm_group_label>
    <arm_group_label>Group III</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Capable of giving written informed consent, which includes compliance with the&#xD;
             requirements and restrictions listed in the consent form.&#xD;
&#xD;
          -  Age 18 years old or older and able to swallow oral medication.&#xD;
&#xD;
          -  Performance Status score of 0 or 1 according to the Eastern Cooperative Oncology&#xD;
             (ECOG) scale for Dose Escalation Cohort. Subjects with ECOG of 2 can be enrolled for&#xD;
             expansion cohort.&#xD;
&#xD;
          -  Tumor Type criteria as listed in the protocol&#xD;
&#xD;
          -  Fasting glucose &lt; 126mg/dL&#xD;
&#xD;
          -  Male subjects must agree to use one of the contraception methods listed in the&#xD;
             protocol.&#xD;
&#xD;
          -  A female subject is eligible to participate if she is of non-childbearing potential,&#xD;
             and if she is of childbearing potential she must use protocol defined contraception&#xD;
             methods.&#xD;
&#xD;
          -  Calcium phosphate product less than or equal to 4.0 mmol2/L2 (50 mg2/dL2)&#xD;
&#xD;
          -  Adequate organ system function as defined below in the protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Malignancies related to HIV or solid organ transplant.&#xD;
&#xD;
          -  Primary malignant brain tumors.&#xD;
&#xD;
          -  Chemotherapy, radiotherapy, or immunotherapy within 28 days (or 42 days for prior&#xD;
             nitrosoureas or mitomycin C) prior to the first dose of GSK1120212. Chemotherapy&#xD;
             regimens given continuously or on a weekly basis with limited potential for delayed&#xD;
             toxicity are permitted with approval of a GSK Medical Monitor if dosing of that agent&#xD;
             is terminated at least 14 days prior to the first dose of GSK1120212.&#xD;
&#xD;
          -  Use of an investigational anti-cancer drug within 28 days or 5 half-lives, whichever&#xD;
             is shorter preceding the first dose of GSK1120212 - as long as a minimum of 14 days&#xD;
             has passed between the last dose of the prior investigational anti-cancer drug and the&#xD;
             first dose of GSK1120212.&#xD;
&#xD;
          -  Previous treatment with an mTOR inhibitor unless approved by GSK Medical Monitor.&#xD;
&#xD;
          -  Previous treatment with GSK1120212.&#xD;
&#xD;
          -  History of sensitivity to any of the study medications, or components thereof or a&#xD;
             history of drug or other allergy that, in the opinion of the investigator or GSK&#xD;
             Medical Monitor, contraindicates their participation.&#xD;
&#xD;
          -  Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs&#xD;
             chemically related to the study drug, DMSO, or excipients. (To date there are no known&#xD;
             FDA approved drugs chemically related to GSK1120212).&#xD;
&#xD;
          -  Use of a prohibited medication (as defined in the protocol).&#xD;
&#xD;
          -  Current use of anticoagulants (e.g. warfarin, heparin) at therapeutic levels within&#xD;
             seven days prior to the first dose of GSK1120212. Low dose (prophylactic) low&#xD;
             molecular weight heparin (LMWH) is permitted provided that subject's PT and PTT meet&#xD;
             entry criteria. Subjects required therapeutic levels of LMWH must receive approval&#xD;
             from GSK Medical Monitor and monitored appropriately as clinically indicated.&#xD;
&#xD;
          -  Gastrointestinal disease predicted to interfere with absorption of an oral drug,&#xD;
             systemic disease, major surgery, or social/psychological issues that in the opinion of&#xD;
             investigators would jeopardize compliance with protocol.&#xD;
&#xD;
          -  History of retinal vein occlusion (RVO) or central serous retinopathy (CSR).&#xD;
&#xD;
          -  Predisposing factors to RVO including uncontrolled hypertension, uncontrolled&#xD;
             diabetes, uncontrolled hyperlipidemia, and coagulopathy.&#xD;
&#xD;
          -  Visible retinal pathology as assessed by ophthalmologic exam that is considered a risk&#xD;
             factor for RVO or CSR.&#xD;
&#xD;
          -  Intraocular pressure &gt; 21mm Hg as measured by tonography.&#xD;
&#xD;
          -  Glaucoma diagnosed within 1 month prior to study Day 1.&#xD;
&#xD;
          -  Symptomatic or untreated leptomeningeal or brain metastases or spinal cord&#xD;
             compression. Subjects previously treated for these conditions that are asymptomatic&#xD;
             and off corticosteroids for at least two weeks are permitted. Subjects are not&#xD;
             permitted to receive enzyme inducing anti-epileptic drugs (EIAEDs).&#xD;
&#xD;
          -  Unresolved toxicity greater than common terminology criteria for adverse events&#xD;
             (CTCAE) grade 1 from previous anti-cancer therapy except alopecia (if applicable)&#xD;
             unless agreed to by a GSK Medical Monitor and the Investigator.&#xD;
&#xD;
          -  History of acute coronary syndromes (including unstable angina), coronary angioplasty,&#xD;
             or stenting within the past 24 weeks.&#xD;
&#xD;
          -  QTc interval â‰¥ 480 msecs.&#xD;
&#xD;
          -  Class II, III, or IV heart failure as defined by the New York Heart Association (NYHA)&#xD;
             functional classification system.&#xD;
&#xD;
          -  Pregnant or lactating female.&#xD;
&#xD;
          -  History or active hepatitis B or C.&#xD;
&#xD;
          -  History of HIV infection.&#xD;
&#xD;
          -  Subjects on chronic antifungal therapy.&#xD;
&#xD;
          -  Unwillingness or inability to follow the procedures outlined in the protocol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Paris Cedex 20</city>
        <zip>75970</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <study_first_submitted>August 6, 2009</study_first_submitted>
  <study_first_submitted_qc>August 6, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 10, 2009</study_first_posted>
  <last_update_submitted>November 7, 2017</last_update_submitted>
  <last_update_submitted_qc>November 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>GSK1120212, everolimus, solid tumors, pancreatic cancer, non-small lung cancer, KRAS-mutant</keyword>
  <keyword>cancer</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Trametinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

